

Recent Advances in the Management of Patients with Advanced Hepatocellular Carcinoma: How Does Your Approach Compare with the Experts?

Reference	Link
Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. <i>J Clin Oncol.</i> 2022;40(4 suppl):379. doi:10.1200/JCO.2022.40.4_suppl.379	https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.4_suppl.379
Abou-Alfa GK, Meyer T, Cheng A, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. <i>N Engl J Med.</i> 2018;379:54-63. doi:10.1056/NEJMoa1717002	https://www.nejm.org/doi/full/10.1056/nejmoa1717002
Abu-Sbeih H, Styskel B, Blechacz B, et al. Clinically significant hepatotoxicity due to immune checkpoint inhibitors is rare but leads to treatment discontinuation in a high proportion. <i>Hepatology.</i> 2018;68(suppl 1):25A-26A(abstract 39). doi:10.1002/hep.30256	https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.30256
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. <i>J Clin Oncol.</i> 2018;36:1714-1768. doi:10.1200/JCO.2017.77.6385	https://pubmed.ncbi.nlm.nih.gov/29442540/
Bruix J, Qin S, Merle, P et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial <i>Lancet.</i> 2017;389:56-66. doi:10.1016/S0140-6736(16)32453-9	https://pubmed.ncbi.nlm.nih.gov/27932229/
El-Khoueiry AB, Melero I, Yau TC, et al. Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040. <i>J Clin Oncol.</i> 2018;36(4 suppl):475. doi:10.1200/JCO.2018.36.4_suppl.475	https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.475
El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. <i>Lancet.</i> 2017;389:2492-2502. doi:10.1016/S0140-6736(17)31046-2	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31046-2/fulltext

<p>El-Khoueiry AB, Yau T, Kang Y, et al. Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040. <i>J Clin Oncol.</i> 2021;39(3 suppl):269. doi:10.1200/JCO.2021.39.3_suppl.269</p>	<p>https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.269</p>
<p>Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. <i>N Engl J Med.</i> 2020;382:1894-1905. doi:10.1056/NEJMoa1915745</p>	<p>https://www.nejm.org/doi/10.1056/NEJMoa1915745</p>
<p>Finn RS, Qin S, Ikeda M, et al. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). <i>J Clin Oncol.</i> 2021;39(3 suppl):267. doi:10.1200/JCO.2021.39.3_suppl.267</p>	<p>https://ascopubs.org/doi/10.1200/JCO.2021.39.3_suppl.267</p>
<p>Jennings JJ, Mandaliya R, Nakshabandi A, Lewis JH. Hepatotoxicity induced by immune checkpoint inhibitors: A comprehensive review including current and alternative management strategies. <i>Expert Opin Drug Metab Toxicol.</i> 2019;15:231-244. doi:10.1080/17425255.2019.1574744</p>	<p>https://pubmed.ncbi.nlm.nih.gov/30677306/</p>
<p>Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. <i>Lancet.</i> 2018;391:1163-1173. doi:10.1016/S0140-6736(18)30207-1</p>	<p>https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30207-1/fulltext</p>
<p>Li D, Sedano S, Allen R, Gong J, Cho M, Sharma S. Current treatment landscape for advanced hepatocellular carcinoma: Patient outcomes and the impact on quality of life. <i>Cancers (Basel).</i> 2019;11:841. doi:10.3390/cancers11060841</p>	<p>https://pubmed.ncbi.nlm.nih.gov/31216701/</p>
<p>Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. <i>Nat Rev Clin Oncol.</i> 2018;15:599-616. doi:10.1038/s41571-018-0073-4</p>	<p>https://pubmed.ncbi.nlm.nih.gov/30061739/</p>
<p>Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. <i>N Engl J Med.</i> 2008;359:378-390. doi:10.1056/NEJMoa0708857</p>	<p>https://www.nejm.org/doi/full/10.1056/nejmoa0708857</p>
<p>Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. <i>Eur J Cancer.</i> 2016;54:139-148. doi:10.1016/j.ejca.2015.11.016</p>	<p>https://pubmed.ncbi.nlm.nih.gov/26765102/</p>
<p>Miller ED, Abu-Sbeih H, Styskel B, et al. Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors. <i>Am J Gastroenterol.</i> 2020;115:251-261. doi:10.14309/ajg.0000000000000398</p>	<p>https://pubmed.ncbi.nlm.nih.gov/31789632/</p>

<p>Wai Ling Khoo TS, Rehman A, Olynyk JK. Tyrosine kinase inhibitors in the treatment of hepatocellular carcinoma. In: Tirnitz-Parker JEE, ed. <i>Hepatocellular Carcinoma</i>. Codon Publications; 2019. Figure 1. BCLC staging system and treatment strategy. doi:10.15586/hepatocellularcarcinoma.2019.ch7</p>	<p>https://www.ncbi.nlm.nih.gov/books/NBK549199/figure/Ch7-f0001/</p>
<p>Yau T, Kang YK, Kim TY. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The CheckMate 040 randomized clinical trial. <i>JAMA Oncol.</i> 2020;6:e204564. doi:10.1001/jamaoncol.2020.4564</p>	<p>https://jamanetwork.com/journals/jamaoncology/fullarticle/2771012</p>
<p>Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncol.</i> 2019;20:282-296. doi:10.1016/S1470-2045(18)30937-9</p>	<p>https://pubmed.ncbi.nlm.nih.gov/30665869/</p>